Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 9/20 | 0.42 |
| ▸ | CDK7 | P50613 | 7/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904714 | 1.00 | ALK (0.48) | ALKCDK9CDK7METULK1 | |
| SCHEMBL30833643 | 0.87 | ALK (0.43) | ALKCDK9CDK7METMAPK8 | |
| SCHEMBL2060756 | 0.80 | LRRK2 (0.43) | ALKCDK9ULK1CCNA2CDK2 | |
| SCHEMBL29435445 | 0.80 | ALK (0.54) | ALKMET | |
| SCHEMBL2061222 | 0.80 | ALK (0.71) | ALKCDK9CDK7METMAPK8 | |
| SCHEMBL31512671 | 0.80 | ALK (0.71) | ALKCDK9CDK7METMAPK8 | |
| SCHEMBL542158 | 0.80 | ALK (0.54) | ALKMET | |
| SCHEMBL2061884 | 0.80 | BPTF (0.44) | ALKCDK9CDK7ULK1CCNA2 | |
| SCHEMBL18812831 | 0.79 | CCNA2 (0.41) | ALKCDK9CDK7ULK1CCNA2 | |
| SCHEMBL2916138 | 0.79 | ALK (0.39) | ALKCDK9CDK7ULK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | ALK 120/4885CDK9 23/4885CDK7 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.